Nanoparticle containing drug that fights cancer genes developedSeptember 16th, 2008 - 3:09 pm ICT by ANI
Washington, Sept 16 (ANI): Scientists at Penn State College of Medicine have devised a safer and more effective way of targeting cancer-causing genes in cancer cells.
They have administered nanoparticles filled with a drug that targets two genes that trigger melanoma cancer.
According to the scientists, the nanomedical approach could offer a potential cure for the cancer.
The new treatment is administered through an ultrasound device and targets cancer-causing genes in cancer cells without harming normal tissue.
“It is a very selective and targeted approach. And unlike most other cancer drugs that inadvertently affect a bunch of proteins, we are able to knock out single genes,” said Gavin Robertson, associate professor of pharmacology, pathology and dermatology, Penn State College of Medicine.
They thought that “silencing RNA” (siRNA), strands of RNA molecules that knock out specific genes, could turn off the two cancer-causing genes and potentially treat the deadly disease more effectively.
“siRNA checks the expression of the two genes, which then lowers the abnormal levels of the cancer causing proteins in cells,” explained Robertson, who is lead author of the study.
Recently, researchers have closed in on two key genes — B-Raf and Akt3 — that cause melanoma. B-Raf, the most frequently mutated gene in melanoma, produces the mutant protein, B-Raf, which helps mole cells survive and grow but does not form melanomas on its own.
They also found earlier that a protein called Akt3 regulates the activity of the mutated B-Raf, which aids the development of melanoma.
Robertson said that the drug used specifically targets Akt3 and the mutant B-Raf and therefore does not affect normal cells.
However, it’’s not easy to knock out specific genes, for delivering the siRNA drug to cancerous cells is rather difficult, as protective layers in the skin not only keep drugs out, but chemicals in the skin quickly degrade the siRNA.
In order to ward off these two problems, the researchers engineered hollow nano-sized particles — nanoliposomes — from globes of fatty acids into which they packed the siRNA.
Later, they used a portable ultrasound device to temporarily create microscopic holes in the surface of the skin, which would enable the drug-filled particles to leak into tumour cells beneath.
“Think of it as tiny basketballs that each protect the siRNA inside from getting degraded by the skin. These basketballs fall through the holes created by the ultrasound and are taken up by the tumor cells, thereby delivering the siRNA drug into the tumor cells,” explained Robertson.
When they exposed lab-generated skin — made from human connective tissue — containing early cancerous lesions to the treatment 10 days after the skin was created, the siRNA reduced the ability of cells containing the mutant B-Raf to multiply by nearly 60 to 70 percent, and more than halved the size of lesions after three weeks.
“This is essentially human skin with human melanoma cells, which provides an accurate picture of how the drug is acting. If you knock down each of these two genes separately, you are able to reduce tumor development somewhat. But knocking them down together leads to synergistic reduction of tumor development,” said Robertson.
The study appeared in the latest issue of the journal Cancer Research. (ANI)
- New hope in the fight against melanoma - Dec 14, 2010
- Broccoli and brussels sprouts boost sunscreens' cancer fighting abilities - Apr 27, 2011
- Zebrafish offers skin cancer clues - Apr 06, 2011
- 'Penicillin' breakthrough in cancer treatment? - Sep 15, 2010
- Proteins key to melanoma development, treatment identified - May 07, 2008
- 'Good cholesterol' nanoparticles may help fight cancer - Apr 02, 2011
- Key enzyme in melanoma cell development found - Jun 18, 2010
- Molecule engineered to attack HIV shows positive results - Jan 20, 2011
- Scientists complete whole-exome sequencing of skin cancer - Apr 16, 2011
- How melanoma tumours evade drug treatment - Nov 25, 2010
- Adopting 'synthetic lethality' could boost molecularly targeted cancer therapy - Sep 22, 2010
- Targeting protein helps keep melanoma tumour growth in check - Dec 10, 2010
- Zebrafish model reveals skin cancer-promoting gene - Mar 24, 2011
- New discovery holds promise for liver cancer treatment - Mar 23, 2011
- New way to slow growth of deadly skin cancer - Jul 09, 2010
Tags: abnormal levels, cancer cells, cancer drugs, cancer genes, cancerous cells, college of medicine, deadly disease, gavin robertson, melanoma, melanoma cancer, mutant protein, penn state college, penn state college of medicine, protective layers, proteins in cells, raf, rna molecules, sirna, strands, ultrasound device